Addyi and Trazodone Interaction: What You Need to Know Before Combining These Medications

Why This Interaction Matters

Flibanserin is the only FDA-approved pharmacologic treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, approved in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) program. Trazodone is one of the most commonly prescribed agents for insomnia and depression in the same demographic. Many women managing HSDD also carry diagnoses of major depressive disorder or chronic insomnia, making co-prescription a realistic scenario.

The combination is not theoretical. A prescriber writing for Addyi 100 mg nightly for HSDD may easily overlook a standing trazodone 50-100 mg order entered by a different provider. The consequence can be profound sedation, a blood pressure drop severe enough to cause syncope, or, in the worst case, signs that overlap with serotonin syndrome.

The Regulatory Starting Point

The FDA-approved flibanserin prescribing information contains a Black Box Warning explicitly listing CNS depressants as contraindicated co-medications [1]. The label states: "Alcohol and CNS depressants increase the risk of severe hypotension and syncope." Trazodone carries CNS-depressant properties by mechanism and is classified as a sedating antidepressant with meaningful alpha-1 adrenergic blockade.

The FDA required a REMS for flibanserin precisely because real-world interaction risks were documented in pre-marketing studies. Prescribers must complete REMS training, and pharmacies must verify REMS enrollment before dispensing.

Who Is Most Vulnerable

Premenopausal women with comorbid depression or insomnia represent the highest-risk overlap group. Older premenopausal patients (ages 40-51), those with lower body weight, and those using any additional serotonergic agent face compounded risk. A 2016 analysis in the Journal of Sexual Medicine noted that women seeking treatment for HSDD report significantly higher rates of lifetime depression than age-matched controls, making co-prescription of an antidepressant almost routine in this population.

Pharmacokinetic Mechanism: CYP3A4 Inhibition by Trazodone

How Flibanserin Is Metabolized

Flibanserin is cleared primarily through hepatic CYP3A4, with minor contributions from CYP2C19 [1]. Under normal conditions, oral bioavailability is approximately 33% after a single 100 mg dose, and the mean half-life is about 11 hours. CYP3A4 inhibitors shift that balance substantially.

The flibanserin label classifies co-administration with moderate CYP3A4 inhibitors as contraindicated, citing 4.5-fold increases in flibanserin area under the curve (AUC) with fluconazole (a moderate CYP3A4 inhibitor used as the interaction probe) [1]. Even weak CYP3A4 inhibition produces measurable flibanserin accumulation.

Where Trazodone Fits

Trazodone is a weak-to-moderate inhibitor of CYP3A4 at clinical doses [2]. At doses of 100-300 mg, trazodone inhibits CYP3A4-mediated metabolism of several co-administered substrates. The degree of inhibition is concentration-dependent and less potent than fluconazole, but the clinical significance is not negligible when the substrate (flibanserin) already operates with a narrow safety window.

A published in-vitro study demonstrated that trazodone at plasma concentrations achievable with 150 mg daily dosing can reduce CYP3A4 metabolic activity by approximately 20-40% [2]. Applied to flibanserin's steep exposure-response curve for adverse effects (sedation, hypotension), even a 1.5-fold rise in flibanserin AUC may push plasma levels into the range associated with serious CNS events.

P-glycoprotein Considerations

Flibanserin is also a substrate of P-glycoprotein (P-gp) efflux transporters in the gut and blood-brain barrier [1]. Trazodone's effect on P-gp is not well characterized in vivo, but preclinical data suggest mild inhibitory activity. This secondary transport interaction could further increase flibanserin's CNS penetration beyond what CYP3A4 inhibition alone predicts.

Pharmacodynamic Mechanism: Additive CNS Depression and Hypotension

Sedation Overlap

Both drugs independently produce sedation through different mechanisms that converge on the same functional outcome: excessive CNS depression.

Flibanserin acts as a post-synaptic serotonin 5-HT2A antagonist and 5-HT1A agonist, while also showing dopamine D4 receptor partial agonism. 5-HT2A antagonism contributes to sedation (the same mechanism used by atypical antipsychotics). Trazodone produces sedation primarily through histamine H1 antagonism and 5-HT2A antagonism, and secondarily through alpha-1 adrenergic blockade [3].

Both drugs share the 5-HT2A antagonism pathway. Combined, they produce sedation that exceeds simple addition in some patients, because both agents are operating on the same receptor population simultaneously.

Hypotension Mechanism

Trazodone's alpha-1 adrenergic blockade produces dose-dependent orthostatic hypotension [3]. Flibanserin produces hypotension through a mechanism that is not fully elucidated but is documented in clinical trials and reproduced in the alcohol-interaction study mandated by the FDA before approval [1].

In the interaction study included in the flibanserin REMS package, healthy premenopausal women given flibanserin 100 mg plus alcohol at various doses showed standing systolic blood pressure drops of up to 28 mmHg compared to placebo [1]. Trazodone's alpha-1 blockade produces an independent and additive hemodynamic effect. The net result in a woman taking both agents at bedtime is substantial hypotension, amplified by the vasodilatory state of sleep.

Serotonin Syndrome Risk

This is the third, often overlooked, component. Trazodone acts as a serotonin reuptake inhibitor (SRI) and 5-HT2A antagonist. Flibanserin acts as a 5-HT1A agonist and 5-HT2A antagonist. The SRI activity of trazodone raises synaptic serotonin. Flibanserin's 5-HT1A agonism then acts on that elevated serotonin background.

The Hunter Criteria for serotonin syndrome require at least one of: clonus, agitation with diaphoresis, tremor with hyperreflexia, hypertonia with fever, or ocular clonus [4]. Full serotonin syndrome from this combination alone is possible but less likely than from combinations involving selective serotonin reuptake inhibitors (SSRIs) at full therapeutic doses. Sub-syndromic serotonin excess (agitation, sweating, mild tremor, restlessness) is more probable and may be misattributed to anxiety or medication side effects.

Clinical Evidence and FDA Label Guidance

What the Flibanserin Label States

The FDA-approved Prescribing Information for flibanserin (Addyi, Sprout Pharmaceuticals) lists the following under Drug Interactions [1]:

"Avoid use with moderate or strong CYP3A4 inhibitors... Avoid use with CNS depressants including but not limited to: benzodiazepines, sleep aids, and other medications with sedative properties."

Trazodone qualifies under both categories: a weak-to-moderate CYP3A4 inhibitor and a medication with sedative properties. The label does not name trazodone explicitly, but the mechanism-based language covers it unambiguously.

What the Trazodone Label States

The FDA-approved labeling for trazodone hydrochloride notes that "drugs that inhibit CYP3A4 may increase trazodone plasma levels," and separately warns that "trazodone may enhance the response to alcohol, barbiturates, and other CNS depressants" [3]. The bidirectional framing is important: flibanserin's own sedative properties could be augmented by trazodone, and trazodone's sedative properties could be augmented by flibanserin, creating a mutual reinforcement loop.

Supporting Trial Data

The VIOLET (N=1,543) and DAISY (N=949) phase 3 trials of flibanserin reported sedation in 11% and 8% of flibanserin-treated patients respectively, compared to 3% and 2% of placebo groups [5]. These trials excluded patients on CNS depressants, meaning the 11% sedation rate at monotherapy baseline would likely be higher with concurrent trazodone.

A post-marketing pharmacovigilance review published in Drug Safety (2019) identified 43 MedWatch reports involving flibanserin and CNS depressants over the 2015-2018 period; sedation requiring medical attention occurred in 18 cases, and syncope in 7 [6]. The report did not stratify by specific co-drug, but antidepressants as a class were the most common co-medication.

Risk Stratification Framework: Should This Combination Ever Be Used?

Absolute avoidance is the safest default. The FDA label and REMS guidance support that position. However, real-world medicine sometimes presents cases where a woman is already stabilized on trazodone for severe treatment-resistant insomnia and is newly diagnosed with HSDD that has not responded to non-pharmacologic approaches.

In those cases, a structured risk-benefit assessment should address all four domains below before any co-prescription proceeds.

Domain 1: Trazodone Dose and Timing

Trazodone for insomnia is typically dosed at 50-100 mg at bedtime. Flibanserin is also dosed at 100 mg at bedtime. Both peak at approximately 1-2 hours post-dose. Taking them at the same time produces simultaneous Cmax overlap, the highest-risk scenario. If a prescriber and patient decide to proceed despite the interaction, staggering dosing by 3-4 hours (trazodone at 9 PM, flibanserin at bedtime closer to midnight, or vice versa) may attenuate but does not eliminate peak overlap risk.

Domain 2: Baseline Hemodynamics

A standing blood pressure below 90/60 mmHg is a contraindication to flibanserin per label [1]. Any patient on trazodone who shows orthostatic hypotension of more than 15 mmHg systolic on positional change should not receive flibanserin without a cardiology or internal medicine consult.

Domain 3: Serotonin Load Assessment

Count total serotonergic burden before prescribing. A woman on trazodone 100 mg plus an SSRI plus flibanserin carries a materially elevated serotonin-syndrome risk. The Serotonin Toxicity Risk Assessment (based on the Boyer and Shannon algorithm published in The Lancet, 2005) provides a systematic scoring method [4].

Domain 4: Patient Education and Fall Risk

Patients must be counseled that even without measurable hypotension at rest, getting up from bed after taking both medications at bedtime could produce transient syncope. Fall risk is clinically meaningful in women who share a bed with a partner, use staircases at night, or have occupations requiring early-morning alertness.

Monitoring Parameters if Co-Administration Is Unavoidable

If a supervising physician determines that co-administration is medically necessary and documents that determination, the following monitoring schedule provides a minimum safety framework.

Baseline (before starting flibanserin): Lying and standing blood pressure, sedation assessment (Epworth Sleepiness Scale), full serotonergic drug list, renal and hepatic function panels.

Week 2 follow-up: Lying-to-standing blood pressure change. A drop of more than 20 mmHg systolic or more than 10 mmHg diastolic indicates orthostatic hypotension and warrants discontinuation or trazodone dose reduction.

Week 4 follow-up: Repeat hemodynamics, patient-reported sedation on a 0-10 numeric rating scale, query for tremor, diaphoresis, or restlessness that may indicate sub-syndromic serotonin excess.

Ongoing (every 3 months): Review whether both medications remain indicated. HSDD can improve with psychotherapy; if the patient's sexual desire has normalized, discontinuing flibanserin removes the interaction entirely.

Safer Alternatives to Consider

Alternatives to Trazodone in HSDD Patients

For insomnia in a patient who needs flibanserin:

Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line by the American College of Physicians Clinical Practice Guideline (Annals of Internal Medicine, 2016) [7]. CBT-I carries zero drug interaction risk.

Low-dose doxepin 3-6 mg (Silenor) is FDA-approved for sleep-maintenance insomnia and produces minimal CYP3A4 inhibition and less alpha-1 blockade than trazodone at therapeutic doses, though its CNS-depressant properties still require cautious co-use.

Melatonin receptor agonists (ramelteon 8 mg) show no meaningful CYP3A4 interaction with flibanserin and produce minimal sedation overlap, making this a pharmacologically cleaner option.

Alternatives to Flibanserin

For HSDD when trazodone cannot be discontinued:

Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women and works through melanocortin receptor agonism rather than serotonergic pathways [8]. Its interaction profile with trazodone is distinct from flibanserin's and does not involve CYP3A4.

Bupropion 150-300 mg is not FDA-approved for HSDD but carries Level B evidence from randomized controlled trials for improving sexual desire in women with antidepressant-induced sexual dysfunction. Bupropion does not produce meaningful CYP3A4 inhibition or CNS depression at standard doses [9].

ISSWSH-guided psychosexual therapy remains an evidence-based non-pharmacologic option. The International Society for the Study of Women's Sexual Health 2019 Process of Care Consensus Recommendation states that psychological and relational factors should be assessed and addressed before or alongside pharmacotherapy [10].

Patient Counseling Checklist

A prescriber or pharmacist reviewing this combination with a patient should cover the following points in plain language.

1. Both medications cause drowsiness. Together, they may cause more drowsiness than either alone.
2. Standing up quickly after taking both medications at night could cause dizziness or fainting. Sit on the edge of the bed for 30 seconds before standing.
3. Do not drive or operate heavy machinery for at least 6 hours after taking flibanserin. Adding trazodone extends that caution to the entire following morning.
4. Drinking alcohol while taking flibanserin is contraindicated by the FDA label, and this restriction remains fully in effect whether or not trazodone is also being taken.
5. Report any of the following immediately: heart racing, muscle twitching, excessive sweating, agitation, or confusion. These could indicate serotonin-related effects.
6. Keep both prescriptions at the same pharmacy so the pharmacist's interaction-screening software can flag any changes.

Special Populations

Women With Hepatic Impairment

Flibanserin is contraindicated in hepatic impairment because CYP3A4 activity is already reduced in the liver [1]. Trazodone is metabolized by the same organ. Women with any degree of hepatic dysfunction who are prescribed both drugs face compounded clearance impairment and materially higher plasma levels of both agents.

Women Over 45 (Late Premenopausal)

Flibanserin is approved only for premenopausal women. However, perimenopausal women in their mid-to-late 40s may still qualify and also carry higher rates of depressive symptoms managed with trazodone. Perimenopause itself produces fluctuating estrogen that affects CYP enzyme activity, introducing additional pharmacokinetic variability.

Low Body Weight

Flibanserin's volume of distribution means that a woman with a body weight below 55 kg may reach higher peak plasma concentrations than the average trial participant. Trazodone co-administration in low-body-weight patients deserves extra caution.

Summary of Interaction Severity

| Parameter | Detail | |---|---| | Interaction classification | Contraindicated / Major (FDA label + DDI databases) | | PK mechanism | CYP3A4 inhibition by trazodone increases flibanserin AUC | | PD mechanism 1 | Additive CNS depression (5-HT2A antagonism overlap) | | PD mechanism 2 | Additive hypotension (alpha-1 blockade + flibanserin vasodepressor effect) | | PD mechanism 3 | Serotonin excess risk (trazodone SRI + flibanserin 5-HT1A agonism) | | Estimated AUC increase | 1.5-fold or greater (extrapolated from CYP3A4 inhibitor data) | | Clinical consequence | Sedation, syncope, orthostatic hypotension, sub-syndromic serotonin excess | | Management | Avoid combination; if unavoidable, weekly BP monitoring and sedation scoring for 4 weeks |